DGIdb - RIMONABANT Drug Record

RIMONABANT chembl:CHEMBL111

Alternate Names:

SR-141716
SR-141716A
ACOMPLIA
SR-14171
RIMONABANT
SR 141716
A 281
chemidplus:168273-06-1
pubchem.compound:104850
chembl:CHEMBL111
drugbank:06155

Drug Info:

FDA Approval	not approved
Drug Class	Small Molecule
Drug Indications	antiobesity agent
Drug Class	appetite-depressants
Year of Approval	not approved by the fda

(0 More Sources)

Publications:

Wu CH et al., 2009, Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice., J Med Chem
Manca I et al., 2013, Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake., Eur J Med Chem
Cawston EE et al., 2015, Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors., J Med Chem
Tseng SL et al., 2008, Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists., J Med Chem
Kumar Srivastava B et al., 2008, Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist., Bioorg Med Chem Lett
Shire et al., 1996, Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A., J. Biol. Chem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Wittgen HG et al., 2011, Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4., Drug Metab Dispos

RIMONABANT CNR1

Interaction Score: 2.76

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Rimonabant

Novel drug target Established target

PMIDs:
19530697 23357307 26203658 18712856 18585913 8636122 11752352

Sources:
DTC TdgClinicalTrial TEND
RIMONABANT ABCC3

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21511945

Sources:
DTC
RIMONABANT ABCC4

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21511945

Sources:
DTC
RIMONABANT ABCC1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21511945

Sources:
DTC
RIMONABANT ABCC2

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21511945

Sources:
DTC
RIMONABANT GMNN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RIMONABANT AR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: RIMONABANT
- Version: 01-August-2011
Alternate Names:

RIMONABANT Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class appetite-depressants

Publications:
TdgClinicalTrial: RIMONABANT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiobesity agent

Drug Class Small Molecule

FDA Approval not approved

Publications:

DTC: RIMONABANT

Version: 02-September-2020

Alternate Names:

CHEMBL111 ChEMBL Drug ID

Drug Info:

Publications:

Manca I et al., 2013, Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake., Eur J Med Chem

Tseng SL et al., 2008, Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists., J Med Chem

Wu CH et al., 2009, Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice., J Med Chem

ChemblDrugs: chembl:CHEMBL111
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	Rimonabant
Novel drug target	Established target

RIMONABANT Drug Record

RIMONABANT chembl:CHEMBL111

Alternate Names:

Drug Info:

Publications:

RIMONABANT CNR1

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name Rimonabant Novel drug target Established target

PMIDs: 19530697 23357307 26203658 18712856 18585913 8636122 11752352

Sources: DTC TdgClinicalTrial TEND

RIMONABANT ABCC3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21511945

Sources: DTC

RIMONABANT ABCC4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21511945

Sources: DTC

RIMONABANT ABCC1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21511945

Sources: DTC

RIMONABANT ABCC2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21511945

Sources: DTC

RIMONABANT GMNN

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

RIMONABANT AR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: RIMONABANT

Alternate Names: RIMONABANT Primary Drug Name

Drug Info: Year of Approval not approved by the fda Drug Class appetite-depressants

Publications:

TdgClinicalTrial: RIMONABANT

Alternate Names:

Drug Info: Drug Indications antiobesity agent Drug Class Small Molecule FDA Approval not approved

Publications:

DTC: RIMONABANT

Alternate Names: CHEMBL111 ChEMBL Drug ID

Drug Info:

ChemblDrugs: chembl:CHEMBL111

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Rimonabant

Novel drug target Established target

PMIDs:
19530697 23357307 26203658 18712856 18585913 8636122 11752352

Sources:
DTC TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
21511945

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21511945

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21511945

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21511945

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

RIMONABANT Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class appetite-depressants

Drug Info:

Drug Indications antiobesity agent

Drug Class Small Molecule

FDA Approval not approved

Alternate Names:

CHEMBL111 ChEMBL Drug ID